Association between fatty liver disease and hearing impairment in Korean adults: a retrospective cross-sectional study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: We hypothesized that fatty liver disease (FLD) is associated with a high prevalence of hearing loss (HL) owing to metabolic disturbances. This study aimed to evaluate the association between FLD and HL in a large sample of the Korean population. Methods: We used a dataset of adults who underwent routine voluntary health checkups (n=21,316). Fatty liver index (FLI) was calculated using Bedogni’s equation. The patients were divided into two groups: the non-FLD (NFLD) group (n=18,518, FLI <60) and the FLD group (n=2,798, FLI ≥60). Hearing thresholds were measured using an automatic audiometer. The average hearing threshold (AHT) was calculated as the pure-tone average at four frequencies (0.5, 1, 2, and 3 kHz). HL was defined as an AHT of >40 dB. Results: HL was observed in 1,370 (7.4%) and 238 patients (8.5%) in the NFLD and FLD groups, respectively (p=0.041). Compared with the NFLD group, the odds ratio for HL in the FLD group was 1.16 (p=0.040) and 1.46 (p<0.001) in univariate and multivariate logistic regression analyses, respectively. Linear regression analyses revealed that FLI was positively associated with AHT in both univariate and multivariate analyses. Analyses using a propensity score-matched cohort showed trends similar to those using the total cohort. Conclusion: FLD and FLI were associated with poor hearing thresholds and HL. Therefore, active monitoring of hearing impairment in patients with FLD may be helpful for early diagnosis and treatment of HL in the general population.
Abstract
Background: We hypothesized that fatty liver disease (FLD) is associated with a high prevalence of hearing loss (HL) owing to metabolic disturbances. This study aimed to evaluate the association between FLD and HL in a large sample of the Korean population. Methods: We used a dataset of adults who underwent routine voluntary health checkups (n=21,316). Fatty liver index (FLI) was calculated using Bedogni’s equation. The patients were divided into two groups: the non-FLD (NFLD) group (n=18,518, FLI <60) and the FLD group (n=2,798, FLI ≥60). Hearing thresholds were measured using an automatic audiometer. The average hearing threshold (AHT) was calculated as the pure-tone average at four frequencies (0.5, 1, 2, and 3 kHz). HL was defined as an AHT of >40 dB. Results: HL was observed in 1,370 (7.4%) and 238 patients (8.5%) in the NFLD and FLD groups, respectively (p=0.041). Compared with the NFLD group, the odds ratio for HL in the FLD group was 1.16 (p=0.040) and 1.46 (p<0.001) in univariate and multivariate logistic regression analyses, respectively. Linear regression analyses revealed that FLI was positively associated with AHT in both univariate and multivariate analyses. Analyses using a propensity score-matched cohort showed trends similar to those using the total cohort. Conclusion: FLD and FLI were associated with poor hearing thresholds and HL. Therefore, active monitoring of hearing impairment in patients with FLD may be helpful for early diagnosis and treatment of HL in the general population.
참고문헌 (31)
- "Deafness and hearing loss" (2023)[URL]
- Przewoźny T, "Hypertension and cochlear hearing loss", Blood Press, 24, pp.199~205 (2015)
- Kang SH, "Visceral fat area determined using bioimpedance analysis is associated with hearing loss", Int J Med Sci, 12, pp.946~951 (2015)
- Kang SH, "Association between HbA1c level and hearing impairment in a nondiabetic adult population", Metab Syndr Relat Disord, 14, pp.129~134 (2016)
- Rim HS, "Association of metabolic syndrome with sensorineural hearing loss", J Clin Med, 10, pp.4866~ (2021)
- Samocha-Bonet D, "Diabetes mellitus and hearing loss : a review", Ageing Res Rev, 71, pp.101423~ (2021)
- Ahmed A, "Nonalcoholic fatty liver disease review : diagnosis, treatment, and outcomes", Clin Gastroenterol Hepatol, 13, pp.2062~2070 (2015)
- Chalasani N, "Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis", Am J Gastroenterol, 98, pp.1849~1855 (2003)
- Musso G, "Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis", Hepatology, 37, pp.909~916 (2003)
- Shibata M, "Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men", Diabetes Care, 30, pp.2940~2944 (2007)
- Chen Z, "A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease", Lipids Health Dis, 16, pp.203~ (2017)
- Dai W, "Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis", Medicine(Baltimore), 96, pp.e8179~ (2017)
- Younossi ZM, "The global epidemiology of NAFLD and NASH in patients with type 2 diabetes : a systematic review and meta-analysis", J Hepatol, 71, pp.793~801 (2019)
- Kang SH, "Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus", Int J Med Sci, 16, pp.285~291 (2019)
- Lonardo A, "Nonalcoholic fatty liver disease and chronic kidney disease : epidemiology, pathogenesis, and clinical and research implications", Int J Mol Sci, 23, pp.13320~ (2022)
- Bedogni G, "The Fatty Liver Index : a simple and accurate predictor of hepatic steatosis in the general population", BMC Gastroenterol, 6, pp.33~ (2006)
- Gastaldelli A, "Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population", Hepatology, 49, pp.1537~1544 (2009)
- Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
- Lee YH, "Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease : development, validation and comparison with other scores", PLoS One, 9, pp.e107584~ (2014)
- Poynard T, "The diagnostic value of biomarkers(SteatoTest)for the prediction of liver steatosis", Comp Hepatol, 4, pp.10~ (2005)
- Kotronen A, "Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors", Gastroenterology, 137, pp.865~872 (2009)
- Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease", Dig Liver Dis, 42, pp.503~508 (2010)
- Long MT, "Development and validation of the Framingham steatosis index to identify persons with hepatic steatosis", Clin Gastroenterol Hepatol, 14, pp.1172~1180 (2016)
- Angulo P, "The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
- Vallet-Pichard A, "FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
- Koehler EM, "External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study", Clin Gastroenterol Hepatol, 11, pp.1201~1204 (2013)
- Calori G, "Fatty liver index and mortality : the Cremona study in the 15th year of follow-up", Hepatology, 54, pp.145~152 (2011)
- Kim JH, "Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population", Liver Int, 31, pp.1600~1601 (2011)
- Huang X, "Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese", Medicine(Baltimore), 94, pp.e1682~ (2015)
- Kim SY, "Trends in alcohol consumption for Korean adults from 1998 to 2018 : Korea National Health and Nutritional Examination Survey", Nutrients, 13, pp.609~ (2021)
- Fan JG, "Epidemiology of alcoholic and nonalcoholic fatty liver disease in China", J Gastroenterol Hepatol, 28(Suppl 1), pp.11~17 (2013)